

Ref: 21411/0251/001-0001

Date: 11.11.2019

Medicines and Healthcare products Regulatory Agency  
10 S Colonnade,  
Canary Wharf,  
London,  
E14 4PU

Castle Hill Hospital  
Castle Road  
Cottingham  
East Yorkshire  
HU16 5JQ

Tel: 01482 461903  
Email: james.illingworth@hey.nhs.uk

Dear MHRA

<b>Trial title:</b> The SCAIPEL study: Survival and Quality of life of Cancer Patients with Incidental Pulmonary Embolism Treated with LMWH.		
<b>EudraCT no:</b> 2015-001707-31	<b>IRAS project ID:</b> 156598	<b>Sponsor R&amp;D ref no:</b> R1850
<b>Participating site:</b> Castle Hill Hospital, Castle Road, Cottingham, HU16 5JQ		<b>Principal investigator:</b> Professor Anthony Maraveyas

This is to notify you that the above study terminated early with no sufficient data to analyse.

Given the random nature of the condition, and the multi-site and weekend scanning protocols being recently implemented at Hull University Teaching Hospitals NHS Trust (changes to the service that have been required by NHS service pressures) added to which, the short, often less than 24 hours, window of opportunity to approach patients, has meant that it has been extremely difficult to recruit to the study. Only one patient consented in the 6 months the study was open. The Steering Committee felt there was no remedial action that could turn around the situation and a recommendation was made to stop the study.

Yours sincerely



**James Illingworth**  
R&D Manager